These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29905925)

  • 21. Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay.
    Bianco G; Boattini M; Iannaccone M; Cavallo R; Costa C
    J Antimicrob Chemother; 2020 Oct; 75(10):3075-3076. PubMed ID: 32676660
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying bla
    Sleger T; Gangl E; Pop-Damkov P; Krause KM; Laud PJ; Slee AM; Nichols WW
    J Chemother; 2018 Apr; 30(2):95-100. PubMed ID: 29191131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study.
    Bassetti M; Carannante N; Pallotto C; Righi E; Di Caprio G; Bernardo M; Sodano G; Mallardo E; Francisci D; Sartor A; Graziano E; Tascini C
    J Glob Antimicrob Resist; 2019 Jun; 17():109-111. PubMed ID: 30468915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbapenem-resistant Klebsiella pneumoniae vertebral osteomyelitis in a renal transplant recipient treated with ceftazidime-avibactam.
    Cani E; Moussavi F; Ocheretyaner E; Sharma R; Brown C; Eilertson B
    Transpl Infect Dis; 2018 Apr; 20(2):e12837. PubMed ID: 29359842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of ventriculitis caused by
    Gofman N; To K; Whitman M; Garcia-Morales E
    Am J Health Syst Pharm; 2018 Jul; 75(13):953-957. PubMed ID: 29941534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood.
    Papalini C; Sabbatini S; Monari C; Mencacci A; Francisci D; Perito S; Pasticci MB
    J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
    Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA
    Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.
    Munoz-Price LS; Reeme AE; Buchan BW; Mettus RT; Mustapha MM; Van Tyne D; Shields RK; Doi Y
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antibiotic arms race: current and emerging therapy for
    Plazak ME; Tamma PD; Heil EL
    Expert Opin Pharmacother; 2018 Dec; 19(18):2019-2031. PubMed ID: 30346216
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae.
    Nath S; Moussavi F; Abraham D; Landman D; Quale J
    J Antimicrob Chemother; 2018 Feb; 73(2):431-436. PubMed ID: 29186402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
    Kang Y; Zhou Q; Cui J
    J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
    Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First case of ceftazidime/avibactam administration in home care. ESBL producing Klebsiella pneumoniae bacteremia.
    Torres-Del-Pliego E; Delgado-Mejía E; Gil-Alonso L; Del Mar-Periáñez-Párraga L
    Enferm Infecc Microbiol Clin; 2017 May; 35(5):322-323. PubMed ID: 27712848
    [No Abstract]   [Full Text] [Related]  

  • 37. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
    Romanelli F; De Robertis A; Carone G; Dalfino L; Stufano M; Del Prete R; Mosca A
    New Microbiol; 2020 Jul; 43(3):136-138. PubMed ID: 32596740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy.
    Boattini M; Bianco G; Charrier L; Comini S; Iannaccone M; Almeida A; Cavallo R; De Rosa FG; Costa C
    Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):431-439. PubMed ID: 36806056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report.
    Holyk A; Belden V; Lee JJ; Musick W; Keul R; Britz GW; Lin J
    J Antimicrob Chemother; 2018 Jan; 73(1):254-256. PubMed ID: 29040635
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.